BioWorld

Sep. 4, 2008

Pfizer to Pay Medivation $225M Up Front in Dimebon Deal

Drugmaker Pfizer Inc. will pay a hefty $225 million up front to Medivation Inc. in a deal to co-develop and market Dimebon, the biotech company's experimental drug for Alzheimer's and Huntington's disease. (BioWorld Today) Read More

More Government Funding: SIGA Adds $55M, Emergent Gets $24M

BIO Sets Sights on 2009 for FOBs, Patent Reform

NewCo News: Wintherix Uses Pfizer Library to Find Wnt Inhibitors for Cancer

Osprey Raises $11M to Move Kidney Drug into the Clinic

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for March 19, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...